Private equity

PAG buys Chinese biotech firm as SOE reform gathers pace

This acquisition will be the largest private equity investment in China’s biotechnology industry to date.

Asia-focused private equity firm PAG said on Thursday that it has agreed to acquire a controlling interest in Hisun BioRay Bio-pharmaceutical, another example of state-owned enterprise reform in China.

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media